LDS/Medical Tests/AGXT Gene Mutation Analysis

AGXT Gene Mutation Analysis

AGXT gene is located at position 37.3 on the long arm (q) in chromosome 2 and consists of 11 exons and 10 introns. It is primarily active in the perioxisomes of hepatocytes and encodes for the Alanine-Glyoxylate aminotransferase (AGT) enzyme (EC no.: 2.6.1.44). AGT is a member of class-V pyridoxal phosphate-dependent aminotransferases and is responsible for the detoxification of circulating glyoxylate into glycine. At present, more than 150 mutations and pathogenic variants in the AGXT gene including deletions, insertions, nonsense, missense, and splicing mutations have been identified. Mutations or pathogenic variants in the AGXT gene result in a rare disorder, primary hyperoxaluria type 1. Primary hyperoxaluria type 1 (PH1) is an autosomal recessive disorder caused by mutations in AGXT resulting in a severe deficiency of the AGT enzyme (typically < 1% of normal activity). While most mutations result in loss of protein function, some mutations cause mistargeted recruitment of AGT into the mitochondria where it cannot function.

The deficiency of AGT results in impaired detoxification of glyoxylate to glycine and its diversion towards the formation of excess oxalate resulting in oxaluria. The excess oxalate in the urine combines with calcium to form calcium oxalate crystals which then leads to the formation renal calculi. The deposition of oxalate in renal tubules and damage from calculi can lead to End-Stage Renal Disease (ESRD). Excess plasma oxalate levels (>30 μmol/L) may also lead to the deposition of oxalates into various other sites such as eyes, bones, central nervous system, kidney, heart termed ‘systemic oxalosis’. PH1 alone is present in 70%-80% of the PH patients globally. The incidence of PH1 is 1 to 3 per 1,000,000 individuals and both males and females are equally affected. Onset usually occurs in childhood and adolescence but can occur at any age from infancy to the sixth decade. Patients present with impaired renal function, recurrent kidney stones, and systemic oxalosis. Administration of pyridoxal phosphate (B6) which is a cofactor of AGT has shown efficiency in some patients with specific mutations. Other forms of primary hyperoxaluria (type 2 and type 3) are caused by mutations in the GRHPR and HOGA1 genes respectively. Molecular testing for AGTX mutations is recommended for patients found to have elevations in plasma and/or urine oxalate levels, calcium oxalate calculi, their parents siblings, and offspring.

  • Confirms the diagnosis of Primary Hyperoxaluria Type 1
  • Carrier screening in individuals with a family history of primary hyperoxaluria type 1

Positive: Presence of mutation or pathologic variants in the AGXT gene.

Negative: Absence of mutation or pathologic variants in the AGXT gene.

Negative for mutations analyzed. (No mutations or pathogenic variants in the AGXT gene were detected).

AGXT deletion/duplication analysis by Multiplex Ligation-dependent Probe Amplification (MLPA), Bi-directional sequence analysis of coding exons by Next Generation Sequencing (NGS)/ Massively Parallel Sequencing (MPS), PCR of the recognized mutants.

Whole blood (EDTA, ACD).

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
  • Frozen: unstable
GRHPR gene mutation analysis, HOGA1 gene mutation analysis, routine urinalysis with microscopy, urine oxalate, urine glycolate, plasma oxalate, urea, creatinine, GFR, AGT activity in liver biopsy tissue, computed tomography, and magnetic resonance imaging.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login